CAR T-cell therapy is a cancer treatment that reprograms your own immune cells to recognize and kill cancer cells. Doctors collect a sample of your T-cells (a type of white blood cell), genetically modify them in a lab to detect a specific protein on cancer cells, then infuse millions of those enhanced cells back into your body. The entire process from referral to infusion takes roughly five weeks, and it’s currently approved for several types of blood cancers.
How the Engineered Receptor Works
The “CAR” in CAR T stands for chimeric antigen receptor, a synthetic protein that gets added to the surface of your T-cells. This receptor has three main parts: an outer section that locks onto a specific marker on cancer cells, a middle section anchoring it to the T-cell membrane, and inner signaling sections that flip the T-cell into attack mode once it finds its target.
Most current CAR T products target a protein called CD19, which sits on the surface of certain white blood cells called B-cells. When the engineered receptor grabs onto CD19, the internal signaling components trigger a chain reaction. The T-cell activates, begins dividing rapidly, releases inflammatory signals to recruit more immune activity, and directly kills the cell it’s attached to. One signaling component handles the initial activation, while a second “costimulatory” component keeps the CAR T-cells multiplying and surviving longer in the body.
What makes this approach fundamentally different from how your immune system normally fights threats is that CAR T-cells don’t need cancer cells to present fragments of themselves through the usual immune identification system (called HLA). Normal T-cells can only spot a threat if cells display protein fragments on their surface like a name tag. Cancer cells often stop displaying these tags, making them invisible. The engineered receptor bypasses that system entirely, grabbing the target protein directly from the cell surface.
The Treatment Process, Step by Step
The journey starts with a blood collection procedure called leukapheresis. Blood is drawn from one arm, passed through a machine that separates out white blood cells (including T-cells), and the remaining blood is returned through the other arm. At one academic medical center, this procedure was scheduled and completed within a median of five days after approval.
Those collected T-cells are shipped to a manufacturing facility, where they’re genetically modified to produce the chimeric antigen receptor. The cells are then grown in large numbers over several weeks. From leukapheresis to hospital admission for the infusion, the median wait is about 22 days, though it can stretch to nearly two months depending on the patient’s condition. Some patients need additional chemotherapy during this gap to keep their cancer in check.
Before the modified cells go back in, you receive a short course of chemotherapy called lymphodepletion. This isn’t meant to treat the cancer directly. Instead, it clears space in your immune system for the new cells. Your existing immune cells, including regulatory cells that would normally suppress an aggressive immune response, compete for the same resources the CAR T-cells need to thrive. Lymphodepletion reduces that competition, increases the availability of growth-promoting signals like IL-7 and IL-15, and helps the engineered cells expand and persist once infused. It also reduces tumor burden so the CAR T-cells don’t exhaust themselves too quickly.
The actual infusion is relatively brief, similar to a blood transfusion. After that, you’ll typically stay in the hospital for monitoring. Median hospital stays run about 11 to 12 days, though some patients stay much longer depending on side effects.
How Well It Works
CAR T-cell therapy produces its most dramatic results in blood cancers that have stopped responding to other treatments. For adults with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL), the most common type of aggressive lymphoma, response rates across major clinical trials ranged from 52% to 82%, with complete remission rates between 40% and 59%. Roughly 50% to 70% of treated patients were alive after 12 months.
The durability of those responses matters most. Patients who achieve complete remission by three months have an 80% to 90% chance of staying in remission long term. In one major trial, 40% of patients remained in sustained complete remission after more than 15 months of follow-up. For a population where prior treatments had failed, these numbers represent a significant shift in prognosis.
Results in pediatric acute lymphoblastic leukemia (ALL) were what first put CAR T therapy on the map, with early trials showing high initial response rates, though some children relapsed within months.
Side Effects to Expect
The two most significant side effects are cytokine release syndrome (CRS) and a neurological complication called ICANS.
CRS happens because the activated CAR T-cells and surrounding immune cells release a flood of inflammatory signaling molecules. This can cause fever, low blood pressure, difficulty breathing, and in severe cases, organ dysfunction. It typically develops within the first week or two after infusion. The severity often correlates with how much cancer is present and how aggressively the CAR T-cells are expanding. Mild cases are managed with supportive care, while more serious episodes are treated with medications that block the key inflammatory signals driving the reaction.
ICANS, the neurological side effect, often starts subtly. Early signs include difficulty finding words, confusion, impaired handwriting, and mild tremor. It can progress to more severe symptoms like inability to speak, agitation, or seizures. Hospital teams monitor for these changes twice daily using a standardized scoring system that tests orientation, attention, writing ability, and language. Mild cases may resolve on their own. More significant cases are treated with steroids, which are tapered quickly once symptoms improve. The most serious, though rare, complications include prolonged seizures and brain swelling.
Approved Products and Cost
The FDA has approved six CAR T-cell products for various blood cancers: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti. The first four target cancers involving B-cells (lymphomas and leukemia), while Abecma and Carvykti target multiple myeloma. Each is approved for specific cancer types and stages, generally after other treatments have failed.
The cost is substantial. The drug acquisition alone averages around $391,000 and represents about 75% of total treatment costs. Across different products and studies, prices ranged from roughly $174,000 to $600,000 before factoring in hospitalization, monitoring, and management of side effects. This expense, along with the weeks-long manufacturing timeline, remains one of the biggest barriers to broader access.
Why It Doesn’t Work for Solid Tumors Yet
All currently approved CAR T therapies treat blood cancers, where the cancer cells circulate freely and share a consistent surface marker like CD19. Solid tumors present a fundamentally different challenge on multiple fronts.
First, there’s a physical barrier. Solid tumors are surrounded by a dense layer of structural proteins laid down by specialized cells called cancer-associated fibroblasts. This creates a wall that CAR T-cells struggle to penetrate. The tumor’s blood vessel network is also abnormal, with reduced levels of the adhesion molecules T-cells need to exit blood vessels and enter tissue. The result is that many CAR T-cells simply never reach the tumor.
Second, the environment inside a solid tumor actively suppresses immune function. Tumors recruit immune cells that have been converted into allies, particularly a type of immune cell called tumor-associated macrophages, which are often the most abundant immune population within a tumor. These cells release signals that shut down T-cell activity and expand populations of regulatory T-cells that further dampen the immune response. Low oxygen levels within tumors also push cancer cells and immune cells to ramp up checkpoint molecules, the same “off switches” that checkpoint inhibitor drugs are designed to block.
Third, the metabolism inside tumors creates a hostile chemical environment. Cancer cells consume glucose at extremely high rates, even when oxygen is available, producing large amounts of lactate and acid. This acidic, nutrient-depleted environment directly suppresses CAR T-cell function, reduces their ability to release cancer-killing compounds, and accelerates T-cell exhaustion. Unlike blood cancers, where CAR T-cells can expand freely in the bloodstream, solid tumors essentially starve and silence the very cells sent to destroy them.
Researchers are working on next-generation designs that could address these barriers, including CAR T-cells engineered to resist the suppressive tumor environment or to target multiple surface proteins simultaneously, since solid tumors are far more variable in which markers their cells display.